Your browser doesn't support javascript.
Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models.
Wang, Gan; Yang, Meng-Li; Duan, Zi-Lei; Liu, Feng-Liang; Jin, Lin; Long, Cheng-Bo; Zhang, Min; Tang, Xiao-Peng; Xu, Ling; Li, Ying-Chang; Kamau, Peter Muiruri; Yang, Lian; Liu, Hong-Qi; Xu, Jing-Wen; Chen, Jie-Kai; Zheng, Yong-Tang; Peng, Xiao-Zhong; Lai, Ren.
  • Wang G; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Yang ML; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China.
  • Duan ZL; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Liu FL; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Jin L; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Long CB; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Zhang M; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Tang XP; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Xu L; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Li YC; Sino-African Joint Research Center, Chinese Academy of Science, Wuhan, Hubei, 430074, China.
  • Kamau PM; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Yang L; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Liu HQ; Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Kunming Primate Res
  • Xu JW; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Chen JK; Sino-African Joint Research Center, Chinese Academy of Science, Wuhan, Hubei, 430074, China.
  • Zheng YT; Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, 650201, China.
  • Peng XZ; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China.
  • Lai R; Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, Yunnan, 650031, China.
Cell Res ; 31(1): 17-24, 2021 01.
Article in English | MEDLINE | ID: covidwho-953056
Semantic information from SemMedBD (by NLM)
1. dalbavancin INTERACTS_WITH angiotensin converting enzyme 2
Subject
dalbavancin
Predicate
INTERACTS_WITH
Object
angiotensin converting enzyme 2
2. COVID-19 PROCESS_OF Animal Model
Subject
COVID-19
Predicate
PROCESS_OF
Object
Animal Model
3. Pharmaceutical Preparations PREVENTS COVID-19
Subject
Pharmaceutical Preparations
Predicate
PREVENTS
Object
COVID-19
4. Vaccines PREVENTS COVID-19
Subject
Vaccines
Predicate
PREVENTS
Object
COVID-19
5. angiotensin converting enzyme 2 PART_OF Homo sapiens
Subject
angiotensin converting enzyme 2
Predicate
PART_OF
Object
Homo sapiens
6. Vero Cells LOCATION_OF dalbavancin
Subject
Vero Cells
Predicate
LOCATION_OF
Object
dalbavancin
7. dalbavancin INTERACTS_WITH angiotensin converting enzyme 2
Subject
dalbavancin
Predicate
INTERACTS_WITH
Object
angiotensin converting enzyme 2
8. COVID-19 PROCESS_OF Animal Model
Subject
COVID-19
Predicate
PROCESS_OF
Object
Animal Model
9. Pharmaceutical Preparations PREVENTS COVID-19
Subject
Pharmaceutical Preparations
Predicate
PREVENTS
Object
COVID-19
10. Vaccines PREVENTS COVID-19
Subject
Vaccines
Predicate
PREVENTS
Object
COVID-19
11. angiotensin converting enzyme 2 PART_OF Homo sapiens
Subject
angiotensin converting enzyme 2
Predicate
PART_OF
Object
Homo sapiens
12. Vero Cells LOCATION_OF dalbavancin
Subject
Vero Cells
Predicate
LOCATION_OF
Object
dalbavancin
ABSTRACT
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic worldwide. Currently, however, no effective drug or vaccine is available to treat or prevent the resulting coronavirus disease 2019 (COVID-19). Here, we report our discovery of a promising anti-COVID-19 drug candidate, the lipoglycopeptide antibiotic dalbavancin, based on virtual screening of the FDA-approved peptide drug library combined with in vitro and in vivo functional antiviral assays. Our results showed that dalbavancin directly binds to human angiotensin-converting enzyme 2 (ACE2) with high affinity, thereby blocking its interaction with the SARS-CoV-2 spike protein. Furthermore, dalbavancin effectively prevents SARS-CoV-2 replication in Vero E6 cells with an EC50 of ~12 nM. In both mouse and rhesus macaque models, viral replication and histopathological injuries caused by SARS-CoV-2 infection are significantly inhibited by dalbavancin administration. Given its high safety and long plasma half-life (8-10 days) shown in previous clinical trials, our data indicate that dalbavancin is a promising anti-COVID-19 drug candidate.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Teicoplanin / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 Topics: Vaccines Limits: Animals / Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Teicoplanin / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 Topics: Vaccines Limits: Animals / Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article